We are live on ! Find out more
IVM

InterWest Venture Management Portfolio holdings

AUM $20.6M
1-Year Est. Return 48.5%
This Fund
S&P 500
This Quarter Est. Return
-33.76%
1 Year Est. Return
+48.5%
3 Year Est. Return
-57.65%
5 Year Est. Return
-76.52%
10 Year Est. Return
–
AUM
$53.8M
AUM Growth
-$208M
Cap. Flow
-$164M
Cap. Flow %
-305.44%
Top 10 Hldgs %
100%
Holding
9
New
–
Increased
1
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
GKOS icon
Glaukos
GKOS
+$46.5K

Top Sells

Rank Stock Value
1
BRZE icon
Braze
BRZE
+$141M
2
PMVP icon
PMV Pharmaceuticals
PMVP
+$23.6M

Sector Composition

Rank Sector Weight
1 Healthcare 89.1%
2 Consumer Discretionary 10.9%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PMVP icon
1
PMV Pharmaceuticals
PMVP
$62.9M
$23M 42.78%
1,614,911
-1,620,000
-50% -$23.6M
GKOS icon
2
Glaukos
GKOS
$8.92B
$16M 29.66%
351,244
+980
+0.3% +$46.5K
REAL icon
3
The RealReal
REAL
$1.4B
$5.86M 10.9%
2,354,080
– –
SERA icon
4
Sera Prognostics
SERA
$80.3M
$3.96M 7.37%
2,416,241
– –
EIGR
5
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$3.53M 6.57%
18,700
– –
AGTC
6
DELISTED
Applied Genetic Technologies Corporation
AGTC
$1.08M 2.01%
1,404,515
– –
VERO
7
DELISTED
Venus Concept
VERO
$305K 0.57%
3,992
– –
DARE icon
8
Dare Bioscience
DARE
$19.8M
$76K 0.14%
5,172
– –
BRZE icon
9
Braze
BRZE
$2.65B
– –
-3,394,219
Closed -$141M

Similar funds

RCP
Rho Capital Partners New York $20.4M AUM
LUGPI
Lightspeed Ultimate General Partner IX Menlo Park, California $20.3M AUM 4.78% 1-Year Est. Return
SIC
Starr International Company Zug, Switzerland $19.9M AUM 39.69% 1-Year Est. Return
DOS
David O. Sacks $19.8M AUM 4.02% 1-Year Est. Return
AA
Antipodean Advisors New York $19.5M AUM 6.21% 1-Year Est. Return
CVSCT
C.V. Starr & Co Trust New York $19.4M AUM 28.57% 1-Year Est. Return
VNB
Virginia National Bank Charlottesville, Virginia $21.9M AUM 12.04% 1-Year Est. Return
BEP
Brookside Equity Partners Stamford, Connecticut $22.5M AUM 62.43% 1-Year Est. Return

InterWest Venture Management's Q2 2022 Portfolio in Review

As of Q2 2022, InterWest Venture Management held 9 positions worth $53.8M, down 79% from $262M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

InterWest Venture Management withdrew a net $164M in Q2 2022, closing 1 position and reducing 1 holding. Its most notable exit was Braze, an estimated $141M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 40% a quarter earlier, followed by Consumer Discretionary and Technology.

Against the trend, InterWest Venture Management added an estimated $46.5K to Glaukos.

  • InterWest Venture Management added most to Glaukos in Q2 2022, an estimated $46.5K increase.
  • InterWest Venture Management's biggest Q2 2022 reduction was PMV Pharmaceuticals, cutting an estimated $23.6M.
  • InterWest Venture Management fully exited Braze in Q2 2022, selling an estimated $141M.
  • InterWest Venture Management's ten largest holdings make up 100% of its $53.8M portfolio in Q2 2022.
  • InterWest Venture Management opened 0 new positions and closed 1 in Q2 2022.
  • InterWest Venture Management's portfolio value fell 79% quarter-over-quarter to $53.8M.

Based on InterWest Venture Management's 13F filing for Q2 2022, filed 2 Aug 2022.